FOI 6303 - Breast Cancer Treatment
Date: 13 October 2020 to 13 October 2023
I am researching the incidence and treatment of breast cancer. Could you please provide the number of patients that you have treated in the past three months with the following:
- Abemaciclib + Anastrozole/Exemestane/Letrozole
- Abemaciclib + Fulvestrant
- Alpelisib + Fulvestrant
- Atezolizumab
- Bevacizumab
- Eribulin
- Everolimus + Exemestane
- Fulvestrant as a single agent
- Gemcitabine + Paclitaxel
- Lapatinib
- Neratinib
- Olaparib
- Palbociclib + Anastrozole/Exemestane/Letrozole
- Palbociclib + Fulvestrant
- Pertuzumab + Trastuzumab + Docetaxel
- Ribociclib + Anastrozole/Exemestane/Letrozole
- Ribociclib + Fulvestrant
- Talazoparib
- Transtuzumab + Paclitaxel
- Transtuzumab as a single agent
- Trastuzumab emtansine
- Any other active systemic anti-cancer therapy
- Request ID:6303
- Category:Clinical - Drugs
- Response:
October 2020
Thank you for your recent request under the Freedom of Information Act 2000.
The information you have requested is as follows:
I am researching the incidence and treatment of breast cancer. Could you please provide the number of patients that you have treated in the past three months with the following:
Medway NHS Foundation Trust can confirm that the number of patients treated for breast Cancer from 01/06/2020 to 31/08/2020 is 155 patients:
- Abemaciclib + Anastrozole/Exemestane/Letrozole=0
- Abemaciclib + Fulvestrant=0
- Alpelisib + Fulvestrant =0
- Atezolizumab =<5
- Bevacizumab=0
- Eribulin= <5
- Everolimus + Exemestane=<5
- Fulvestrant as a single agent=0
- Gemcitabine + Paclitaxel=0
- Lapatinib =0
- Neratinib =0
- Olaparib = 0
- Palbociclib + Anastrozole/Exemestane/Letrozole=29
- Palbociclib + Fulvestrant=0
- Pertuzumab + Trastuzumab + Docetaxel=5
- Ribociclib + Anastrozole/Exemestane/Letrozole=<5
- Ribociclib + Fulvestrant=0
- Talazoparib =0
- Transtuzumab + Paclitaxel=<5
- Transtuzumab as a single agent=20
- Trastuzumab emtansine =9
- Any other active systemic anti-cancer therapy=84
